CDC estimates 9.7 million infections annually from AMR threats
-
By
-
Amy Pfeiffer
-
October 29, 2026
-
4 min
Clinical Scorecard: CDC estimates 9.7 million infections annually from AMR threats
At a Glance
Category | Detail |
|---|---|
Condition | Antimicrobial resistance threats and the burden of infections and deaths described in CDC’s 2026 report |
Key Mechanisms | Antibiotic use and pathogen transmission contribute to both C. difficile infections and antimicrobial resistance. The report includes C. difficile although it is not typically drug resistant. |
Target Population | People in the United States affected by the bacterial and fungal pathogens covered by the report |
Care Setting | Health care and community settings; updated C. difficile estimates include infections among patients outside hospitals |
Key Highlights
CDC estimated 9.7 million infections and 50,800 deaths annually in the United States from the pathogens covered by its report, based on 2023 data and updated methods.
More than 9.3 million infections and more than 39,000 deaths involved drug-resistant pathogens. The higher overall totals include C. difficile.
The report identifies 19 bacterial and fungal threats classified as urgent, serious or concerning, plus 6 watch-list pathogens.
Urgent threats are Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales and drug-resistant Neisseria gonorrhoeae.
CDC reclassified C. difficile from urgent to serious, attributing the change partly to improved infection prevention, particularly in health care settings, where infections have declined since 2011.
Seven bacterial threats commonly associated with health care caused more than 42,000 deaths in 2023 and accounted for nearly $12 billion in health care costs.
Guideline-Based Recommendations
The source summarizes a CDC surveillance report and IDSA’s response rather than a clinical guideline.
Diagnosis
The article does not provide diagnostic algorithms, testing indications or patient-level screening recommendations.
CDC’s threat assessment considers clinical and economic impact, infection incidence, projected changes over 5 years, transmissibility, preventability and treatment availability.
Management
IDSA President Wendy S. Armstrong, MD, FIDSA, urged Congress to pass the bipartisan PASTEUR Act.
The legislation is intended to encourage development of new antimicrobial drugs and support antimicrobial stewardship.
The article does not provide drug-selection recommendations, doses or treatment regimens.
Monitoring & Follow-up
Drug-resistant Neisseria meningitidis was added to the serious threat category.
Drug-resistant dermatophytes, drug-resistant Haemophilus influenzae and nontuberculous mycobacteria were added to the watch list.
The watch list also includes azole-resistant Aspergillus fumigatus, drug-resistant Bordetella pertussis and drug-resistant Mycoplasma genitalium.
Estimates for drug-resistant group A Streptococcus and clindamycin-resistant group B Streptococcus now include noninvasive as well as invasive infections.
CDC cautioned against direct comparisons with previous reports because data sources and methods changed substantially for all pathogens except C. auris.
Risks
Armstrong said resistant infections prolong hospital stays, increase health care costs and complicate the safe provision of chemotherapy, organ transplantation, joint replacement and other care.
C. auris can spread in health care facilities and cause severe infections. CDC previously documented a nearly fivefold increase in reported clinical cases between 2019 and 2022.
C. difficile remains an important cause of health care-associated infections despite its revised classification.
Patient & Prescribing Data
The report’s estimates use 2023 data. The overall totals and drug-resistant totals describe different groups: the higher overall figures include C. difficile, which is not typically drug resistant.
Previous CDC analyses found that hospital-onset infections involving 6 drug-resistant bacterial pathogens increased by 20% during the COVID-19 pandemic compared with the prepandemic period. Rates declined after peaking in 2021 but remained above prepandemic levels in 2022.
The article provides no patient-level prescribing or treatment data.
Clinical Best Practices
Distinguish the overall burden estimates, which include C. difficile, from estimates involving drug-resistant pathogens.
Account for changes in data sources and methodology when interpreting comparisons with earlier reports.
Recognize that moving C. difficile to the serious category does not eliminate its substantial infection, mortality and cost burden.
Distinguish updated threat classifications from patient-level treatment recommendations.
Support antimicrobial stewardship and development of new antimicrobial drugs, as urged by IDSA.
Related Resources & Content
CDC estimates 9.7 million infections annually from AMR threats — Amy Pfeiffer — IDSA Reporter — October 29, 2026.
2026 Antimicrobial Resistance Threats Report — Centers for Disease Control and Prevention — Released October 27, 2026 — Linked in the supplied article.
Based on findings from:
CDC estimates 9.7 million infections annually from AMR threats
Amy Pfeiffer. Idsa Reporter, 2026.
https://idsareporter.com/issues/2026/october-2026/cdc-estimates-97-million-infections-and-50-800-deaths-annually-from-antimicrobial-resistance-threats/
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.